Tea Lund Laursen

Tea Lund Laursen

Auto-generated profile, based on publicly available information

Tea Lund Laursen

Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
TLTea Lund Laursen
Tea Lund Laursen
DMDitte Emilie Munk
Ditte Emilie Munk
HVHendrik Vilstrup
Hendrik Vilstrup
KWKarl Heinz Weiss
Karl Heinz Weiss
POPeter Ott
Peter Ott

10 September 2019 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
TLTea Lund Laursen
Tea Lund Laursen
CKCecilie Siggaard Knoph
Cecilie Siggaard Knoph
KKKonstantin Kazankov
Konstantin Kazankov
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
HMHolger Jon Møller
Holger Jon Møller
Henning GrønbækHenning Grønbæk
Henning Grønbæk

26 January 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
TLTea Lund Laursen
Tea Lund Laursen
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
KKKonstantin Kazankov
Konstantin Kazankov
TSThomas Sandahl
Thomas Sandahl
HMHolger Jon Møller
Holger Jon Møller
Henning GrønbækHenning Grønbæk
Henning Grønbæk

14 June 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
TLTea L Laursen
Tea L Laursen
TSThomas D Sandahl
Thomas D Sandahl
KKKonstantin Kazankov
Konstantin Kazankov
JGJacob George
Jacob George
Henning GrønbækHenning Grønbæk
Henning Grønbæk
Liver-related effects of chronic hepatitis C antiviral treatment

27 January 2021 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
SSSidsel Støy
Sidsel Støy
TLTea Lund Laursen
Tea Lund Laursen
LELotte Lindgreen Eriksen
Lotte Lindgreen Eriksen
Henning GrønbækHenning Grønbæk
Henning Grønbæk
HVhendrik vilstrup
hendrik vilstrup
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
INTRODUCTION: In alcoholic hepatitis (AH), translocation of gut bacteria may drive hepatic macrophage activation and systemic inflammation. We investigated the effect of oral non-absorbable, broad-spectrum antibiotic treatment on bacterial translocation and liver and systemic inflammation in AH. METHODS: We consecutively recruited 31 patients with AH. Fourteen were given vancomycin 500 mg, gentamycin 40 mg, and meropenem 500 mg once daily for 7 days. Seventeen patients were a reference group receiving standard-of-care. Circulating markers of bacterial translocation and inflammation were measured at baseline, by day 7 and 90. Gut bacteriome profiling was performed before the intervention and at day 7. RESULTS: At study entry, blood lipopolysaccharide-binding protein was multifold higher than normal, remained unchanged at day 7, but decreased at day 90 (P < 0.001) with no difference between the study groups. The macrophage activation markers sCD163 and sCD206 showed the same pattern (P < 0.001, day 90), still without group differences. The systemic inflammation markers tumor necrosis factor—alpha, interleukin (IL)-6, IL-8, and IL-10 showed similar dynamics without group differences. There was no difference in 90-day mortality (total of 6 deaths) between the groups. The remnant gut bacteriome was markedly diversified by the intervention with growth of bacterial species rare for human flora. DISCUSSION: In patients with AH, gut-targeted antibiotic treatment does not change markers of bacterial translocation and liver and systemic inflammation. This suggests that bacterial translocation is less important once the inflammatory process is established or that bacteriome reduction is less important than composition. JOURNAL/cltg/04.03/01720094-202102000-00001/inline-graphic1/v/2023-10-30T212951Z/r/image-tiff

9 September 2014 in Liver International
Verified
Journal Article
Open access
PDF file
TLTea L. Laursen
Tea L. Laursen
TSThomas D. Sandahl
Thomas D. Sandahl
SSSidsel Støy
Sidsel Støy
FSFrank V. Schiødt
Frank V. Schiødt
WLWilliam M. Lee
William M. Lee
UGUS Acute Liver Failure Study Group
US Acute Liver Failure Study Group
Background & Aims: The complement system is activated in liver diseases including acute liver failure (ALF); however, the role of the lectin pathway of complement has scarcely been investigated in ALF. The pathway is initiated by soluble pattern recognition molecules: mannan‐binding lectin (MBL), M‐, L‐, and H‐ficolin and collectin‐liver‐1 (CL‐L1), which are predominantly synthesized in the liver. We aimed to study lectin levels in ALF patients and associations with clinical outcome.Methods: Serum samples from 75 patients enrolled by the US ALF Study Group were collected on days 1 and 3. We included 75 healthy blood donors and 20 cirrhosis patients as controls. Analyses were performed using sandwich‐type immunoassays (ELISA, TRIFMA).Results: At day 1, the MBL level in ALF patients was 40% lower compared with healthy controls {[median (interquartile range) 0.72 μg/ml(0.91) vs. 1.15 (1.92)(P = 0.02]}, and increased significantly by day 3 [0.83 μg/ml(0.94)(P = 0.01)]. The M‐ficolin level was 60% lower [0.54 μg/ml(0.50) vs. 1.48(1.01)(P < 0.0001)]. The CL‐L1 level at day 1 was slightly higher compared with healthy controls [3.20 μg/ml(2.37) vs. 2.64(0.72)(P = 0.11)]; this was significant at day 3 [3.35(1.84)(P = 0.006)]. H‐ and L‐ficolin levels were similar to healthy controls. Spontaneous ALF survivors had higher levels of MBL at day 1 [0.96 μg/ml(1.15) vs. 0.60(0.60)(P = 0.02)] and lower levels of L‐ficolin by day 3 compared with patients who died or were transplanted [1.61 μg/ml(1.19) vs. 2.17(2.19)(P = 0.02)].Conclusion: We observed significant dynamics in lectin levels in ALF patients, which may suggest they play a role in ALF pathogenesis. High MBL and low L‐ficolin levels are associated with survival.